A chart review study to assess current treatment with Onabotulinumtoxin A in chronic migraine patients in Germany

• Conditions: G43; Migraine

• Registration Number: DRKS00028782
• Lead Sponsor: AbbVie Deutschland GmbH & Co. KG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-05-25
• Study Completion: 2023-03-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 427

Inclusion Criteria

Male and female patients with a diagnosis of Chronic Migraine (CM)

CM Patients with treatment initiation of OnabotulinumtoxinA therapy between Jan 2020 and July 2021 and at least one completed injections cycle

Patients who were at least 18 years old

Exclusion Criteria

Patients who were concomitantly enrolled in interventional studies (enrollment in a registry is not an exclusion criteria)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To describe the effectiveness of OnabotulinumtoxinA treatment on CM in regard to headache days in real world setting of patients treated in-label<br>- Change in number of monthly headache days from start of treatment to the end of the third treatment cycle (9 months).